Objective: The mechanism of the beneficial effect of calcium-channel blockers (CCBs), especially verapamil, on the development of type 2 diabetes mellitus (T2DM) has been described. This study compared the incidence of T2DM in adults prescribed oral verapamil and propensity score-matched adults prescribed other oral CCBs. Results: During follow-up periods of 41,958 and 42,118 person-years, 269 of 4930 patients in the verapamil cohort and 340 of 4930 patients in the matched cohort, respectively, developed T2DM. The incidence rates were 6.41 and 8.07 per 1000 population per year among verapamil and other CCB users, respectively. The adjusted hazard ratio (HR) for T2DM associated with use of verapamil (vs. other CCBs) was 0.80 [95% confidence interval (CI), 0.68 to 0.94; P = 0.006]. After exclusion of patients followed for ,180 days or ,365 days (to avoid bias derived from delayed diagnosis), adjusted HRs remained significant [0.79 (95% CI, 0.67 to 0.93; P = 0.005) and 0.77 (95% CI, 0.65 to 0.91; P = 0.002), respectively]. Only the interaction term for age was significant (P = 0.009). Verapamil had a more prominent effect on patients aged older than 65 years (P , 0.001).
T he number of people with diabetes mellitus (DM) is expected to increase from 171 million in 2000 to at least 366 million by 2030 (1) . The excessive mortality and morbidity of patients with DM cause enormous health care expenditures and loss of productivity. In the United States in 2012, DM affected 22.3 million people, leading to 43.1 million inpatient days, 246,000 deaths, and a total cost of $245 billion per year (2) . Various interventions have been proposed to address the DM epidemic (3, 4) , and several medications have been proposed to decrease the incidence of DM (3) .
A recent study showed that calcium-channel blockers (CCBs), such as verapamil, improved b-cell survival and function, enhanced insulin secretion, and rescued mice from type 2 DM (T2DM) (5) . The effect of CCBs has also been supported by the results of post hoc analyses in several clinical studies (6, 7) . Verapamil was associated with a decreased risk for newly diagnosed T2DM compared with atenolol use in the International Verapamil SR/Trandolapril Study (6, 7) . Another study showed that the use of CCBs, particularly verapamil, was associated with lower fasting blood glucose levels in participants with T2DM (8) . Because CCBs make up a group of chemically diverse drugs, differences in their effects are expected. However, none of these studies determined whether different CCBs have the same effect. A recent in vitro study indicated that the effect of verapamil may be superior to those of other CCBs (5) . Therefore, the current 12-year nationwide population-based study compared the incidence of newly diagnosed T2DM in verapamil users with that in propensity-matched CCB users to determine the effect of verapamil on T2DM.
Methods

Data source
Taiwan's National Health Insurance (NHI) program, launched in 1995, currently covers 99% of the population of 23 million people (9) . The NHI Research Database comprises all registry and claims data from the NHI system, ranging from demographic data to detailed orders for ambulatory and inpatient care. Disease diagnoses are recorded by using codes from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). The Longitudinal Health Insurance Database contains complete data on 1,000,000 beneficiaries sampled randomly from the NHI Research Database. Because the data set used in this study consists of deidentified secondary data released to the public for research purposes, the study was exempted from full review by the institutional review board.
Study design and population
This population-based, observational, retrospective cohort study was conducted to determine whether the use of verapamil can reduce the incidence of newly diagnosed T2DM. We compared the incidence of newly diagnosed T2DM in two prop1ensity score-matched adult (age .20 years) cohorts: those who received prescriptions for oral verapamil and those prescribed other oral CCBs (all drugs other than verapamil with Anatomical Therapeutic Chemical Classification code C08). CCBs other than verapamil were used as comparators because of their lack of metabolic effect. In addition, they shared similar indications with verapamil compared with other classes of antihypertensive drugs. Individuals with previous diagnoses of T2DM were excluded.
We extracted clinical information from the Longitudinal Health Insurance Database covering the period January 2000 to December 2011. The index date was the day of verapamil or other CCB prescription. We also extracted data on each identified individual for the period January 1997 to December 1999 to ensure that all individuals were followed for at least 3 years before study enrollment, thereby confirming the presence of comorbidities (10) and the accuracy of matching (11) . We identified one CCB user for each qualified verapamil user according to the year of prescription, age, sex, urbanization level, income level, number of outpatient visits, underlying conditions, medications, and propensity score (60.1) (12). Both cohorts were followed until diagnosis of T2DM, loss to follow-up, death, or 31 December 2013. The study endpoint was the occurrence of T2DM, confirmed by repeated recording of ICD-9-CM codes (250.x) by physicians, which have been validated and adopted in the previous study (13, 14) .
Statistical analysis
Descriptive statistics were used to characterize the baseline data from the two study cohorts. Propensity scores for the likelihood of verapamil use were calculated by multivariate logistic regression analysis, conditional on the baseline covariates listed in Table 1 . The cumulative incidence of newly diagnosed T2DM was calculated by the Kaplan-Meier method and compared by using the log-rank test. Cox proportional hazards models were used to compute hazard ratios (HRs) and 95% confidence intervals (CIs). We also tested whether the association between verapamil use and T2DM was affected significantly by the interaction of demographic characteristics, socioeconomic status, and/or underlying conditions or medications associated with T2DM by performing likelihood ratio testing of nested models and stratified subgroup analyses. P values , 0.05 were considered to indicate statistically significant differences. Microsoft SQL Server 2008 R2 (Microsoft Corp., Redmond, WA) was used for data linkage, processing, and sampling. All analyses were conducted by using Stata statistical software, version 12.0 (Stata Corp., College Station, TX).
Results
The study cohorts comprised 4930 patients prescribed oral verapamil and the same number of matched patients prescribed oral CCBs. The participants were predominantly female (55.1%), and the mean age was 48.6 (standard deviation, 16.1) years. The median Charlson Comorbidity Index score was 1 (interquartile range, 0 to 2). Beta-blockers were the most common concomitantly used antihypertensive drugs (n = 678; 13.8%), followed by angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEIs/ARBs, n = 170; 3.4%) and diuretics (n = 124; 2.5%). The propensity scores for the likelihood of verapamil and CCB use were similar. The baseline characteristics of the study cohorts are shown in Table 1 .
During follow-up periods of 41,958 and 42,118 person-years, 269 patients in the verapamil cohort and 340 patients in the matched cohort, respectively, developed T2DM ( Table 2 ). The incidence rates were 6.41 and 8.07 per 1000 population per year for users of verapamil and other CCBs, respectively. The HR and adjusted HR for T2DM with use of verapamil were 0.80 (95% CI, 0.68 to 0.93; P = 0.005; Table 2 ) and 0.80 (95% CI, 0.68 to 0.94; P = 0.006; Table 3 ), respectively, compared with use of other CCBs. Sensitivity analyses produced consistent results (Table 3 ). The adjusted HRs in patients with no steroid use or autoimmune disease were 0.82 (95% CI, 0.70 to 0.98; P = 0.024) and 0.81 (95% CI, 0.69 to 0.95; P = 0.009), respectively. The adjusted HRs in those followed for more than 180 and 365 days remained significant [0.79 (95% CI, 0.67 to 0.93; P = 0.005) and 0.77 (95% CI, 0.65 to 0.91; P = 0.002), respectively]. The cumulative incidence of T2DM in the verapamil and matched cohorts also differed significantly (log-rank test, P = 0.005) (Fig. 1) .
Tests of interaction showed that verapamil had more prominent association (interaction term, P = 0.009) in patients aged older than 65 years (adjusted HR, 0.62; 95% CI, 0.49-0.79; P , 0.001) than in those aged 20 to 64 years (adjusted HR, 0.96; 95% CI, 0.77 to 1.20; P = 0.735). The risks for T2DM development associated with verapamil use were consistent in all other subgroups. Detailed findings of subgroups analyses are shown in Table 4 . 
Discussion
The severe complications of T2DM and huge health expenditure associated with the disease justify efforts to prevent or delay its onset. The effectiveness of metformin (3) in reducing T2DM incidence supports adjunctive medication use in selected population. CCBs were previously thought to be superior to beta-blockers and diuretics because of the lack of a metabolic effect. In this population-based study, analyses of matched cohorts that adjusted for various confounding factors further revealed that verapamil had a unique role among CCBs in decreasing the risk for T2DM development. The effect of oral verapamil was observed consistently in different groups, with a greater benefit seen in elderly patients.
The effect of verapamil may derive from its ability to inhibit the expression of thioredoxin-interacting protein (TXNIP) (5). TXNIP, a proapoptotic b-cell factor, plays an important role in glucotoxicity and b-cell death, which is the critical determinant for the development of DM. Overexpression of TXNIP in b cells in response to hyperglycemia promotes oxidative stress, induces cell-cycle arrest and leads to b-cell apoptosis (15). Xu et al. (5) showed that the reduction in intracellular calcium level caused by CCBs leads to decreased TXNIP expression via calcineurin-mediated exclusion of nuclear carbohydrateresponsive element-binding protein, which prevents b-cell death. Their animal study also confirmed the in vivo effect of verapamil in rescuing mice from druginduced DM.
Xu et al. (5) also showed that the effect of verapamil is superior to that of diltiazem. However, few studies have compared the effect of CCBs on T2DM in clinical settings. The International Verapamil SR/Trandolapril Study revealed an association between CCB use and a lower risk for newly diagnosed T2DM (6, 7); comparison of these drugs with atenolol raised concern about the metabolic effects of beta-blockers. In the Reasons for Geographic and Racial Differences in Stroke Study, 1484 CCB users were compared with nonusers, rather than verapamil users, in a national US cohort. In addition, the study endpoint was the serum glucose level instead of T2DM incidence. The design of our study allowed us to identify the superior protective effect of verapamil relative to other CCBs. These findings are not surprising, given the differences among CCBs in chemistry, electrophysiologic action, tissue specificity, and clinical utility that have been observed since their discovery (16, 17) . However, the detailed mechanism underlying verapamil's superiority to other CCBs in protection against T2DM requires further investigation, which may inform novel agent discovery.
In contrast to the increased benefits of metformin in patients aged younger than 60 years (4), our study b Index date was defined as the date of 181 days after enrollment to avoid immortal time bias. c Index date was defined as the date of 366 days after enrollment to avoid immortal time bias. Figure 1 . Cumulative incidence of new-onset DM in patients using verapamil and matched patients using other CCBs. identified a more prominent association of verapamil with reduced incidence of T2DM in elderly patients. This difference may be explained by the complexity of interactions between age-related changes in physiologic condition and drug effects. Differences in the pharmacokinetics and pharmacodynamics of verapamil in elderly and young populations have been shown to result in altered electrocardiographic and hypotensive responses (18, 19) . In view of the increasing burden of T2DM in the elderly population worldwide (1) , further studies of verapamil may be cost-effective and warranted. The metabolic effects of antihypertensive drugs other than CCBs have been reported. The use of ACEIs/ARBs has also been associated with a decreased incidence of newly diagnosed T2DM (20) . In addition to inhibition of the renin-angiotensin system, which affects the translocation of glucose transporter type 4 (21), the insulinsensitizing effect of ACEIs/ARBs may be related to enhancement of the bradykinin-nitric oxide system (22) and activation of peroxisome proliferator-activated receptor-g (23) . In contrast, diuretics and beta-blockers have detrimental effects on glucose metabolism. A reduction in the serum potassium or magnesium level, visceral fat redistribution, and low-grade inflammation are plausible reasons for diuretic-associated T2DM, whereas beta-blockers may affect glucose homeostasis by decreasing blood flow to the muscles, attenuating insulin secretion from pancreatic b cells, and increasing body weight (24, 25) . In addition to antihypertensive drugs, statin has been associated with the development of T2DM. Certain statins may have the negative effect on glucose metabolism via adipocyte maturation and glucose-transporter-4 (26). However, conflicting results were observed in meta-analysis (27) and in Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin trial (28) . The West of Scotland Coronary Prevention Study (29) showed that pravastatin therapy might reduce the risk for T2DM. The mechanism remains elusive. The strengths of our study include the examination of a large cohort of patients without diabetes from a general population; the propensity score-matched design; the consideration of extensive data on diseases and medications during matching and subgroup analyses; and the examination of CCBs, rather than other antihypertensive drugs, as comparators to avoid indication and control selection biases. The limitations of the study include its retrospective design. The diagnosis of T2DM was based on ICD-9-CM codes, rather than laboratory data. However, the universal enrollment of residents of Taiwan in the NHI program ensures the availability of patient data with long follow-up periods, thereby ensuring the accuracy of the definition of T2DM using these codes. This method has also been adopted in other studies (13, 14) . We further excluded patients with shorter follow-up periods to avoid bias derived from delayed diagnosis, and HRs remained significant in these analyses. Another limitation is that our study did not include the general population as comparators to avoid the introduction of indication bias. The incidence of T2DM in the verapamil cohort (6.41/1000 population/year) was lower than that in the general population aged 20 to 79 years during 2000 to 2008 in Taiwan (7.64 to 9.32/1000 population per year) (30) .
In conclusion, this study showed the significant association of verapamil and reduced incidence of newly diagnosed T2DM compared with other CCBs. This association is consistent in different groups and more prominent in elderly patients. Further studies of the specific effects of verapamil may improve our understanding of diabetes pathogenicity and inform the development of preventive strategies.
